Zaldiar 37,5 mg/325 mg comprimidos efervescentes

Leaflet: information for the user

Zaldiar 37.5 mg/325 mg effervescent tablets

Tramadol hydrochloride/Paracetamol

Read this leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
• If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Zaldiar is a combination of two analgesics, tramadol hydrochloride and paracetamol, which act together to relieve pain.

This medication is used in the treatment of moderate to severe pain whenever your doctor believes that the combination of tramadol hydrochloride and paracetamol is necessary.

This medication should only be used by adults and adolescents over 12 years old.

Do not take Zaldiar

• if you are allergic to hydrochloride tramadol, paracetamol, yellow-orange colorant (E110) or any of the other components of this medication (listed in section 6);
• if you have taken any medication for the treatment of insomnia, analgesics or psychotropic medications (medications that can alter mood and emotions) in case of acute alcohol intoxication;
• if you are also taking MAO inhibitors (certain medications used for the treatment of depression or Parkinson's disease) or if you have taken them in the last 14 days before treatment with this medication;
• if you have severe liver disease;
• if you have uncontrolled epilepsy with your current treatment.

Warnings and precautions

Consult your doctor before starting to take Zaldiar, if

• you are taking other medications that contain paracetamol or hydrochloride tramadol;
• you have liver problems or liver disease or if you notice that your eyes or skin turn yellow. This may be indicative of jaundice or problems with your bile ducts;
• you have kidney problems;
• you have severe respiratory difficulties, for example asthma or severe lung problems;
• you are epileptic or have had seizures or convulsions;
• you suffer from depression and are taking antidepressants since some may interact with tramadol (see "Taking Zaldiar with other medications");
• you have recently had a head trauma, shock or severe headaches associated with vomiting;
• you are dependent on any other medication used for pain relief, for example morphine;
• you are taking other medications for pain relief that contain buprenorphine, nalbuphine or pentazocine;
• you are going to be anesthetized. Tell your doctor or dentist that you are taking this medication.

Tolerance, dependence and addiction

This medication contains tramadol, which is an opioid medication. Repeated use of opioids can make the medication less effective (the body becomes accustomed to it, known as pharmacological tolerance). Repeated use of Zaldiar can also cause dependence, abuse and addiction, which could lead to a potentially fatal overdose. The risk of these adverse effects may be higher with a higher dose and longer use.

Dependence or addiction can cause a feeling of lack of control over the amount of medication you should use or the frequency with which you should use it.

The risk of dependence or addiction varies from person to person. The risk of becoming dependent or addicted to Zaldiar may be higher if:

- You or any member of your family have abused alcohol or experienced dependence on it, prescription medications or illegal drugs ("addiction").

- You are a smoker.

- You have had any problems with mood (depression, anxiety or personality disorder) or have followed treatment with a psychiatrist for other mental health conditions.

If you notice any of the following symptoms while using Zaldiar, it could be a sign of dependence or addiction:

– You need to use the medication for a longer period than indicated by your doctor.

– You need to use a higher dose than recommended.

– You are using the medication for reasons other than those prescribed, for example, "to feel calm" or "to help you sleep".

– You have made repeated and unsuccessful attempts to stop using the medication or control its use.

– You feel unwell when you stop using the medication, and you feel better once you take it again ("withdrawal symptoms").

If you notice any of these signs, consult your doctor to determine the best course of treatment for you, when it is appropriate to stop taking the medication and how to do it safely (see section 3, if you interrupt treatment with Zaldiar).

Respiratory problems related to sleep

This medication contains an active ingredient that belongs to the group of opioids. Opioids can cause respiratory problems related to sleep; for example, central sleep apnea (shallow breathing or pauses in breathing during sleep) and sleep-related hypoxemia (low oxygen levels in the blood).

The risk of experiencing central sleep apnea depends on the dose of opioids. Your doctor may consider reducing the total dose of opioids if you experience central sleep apnea.

There is a weak risk that you may experience a serotonin syndrome that can occur after taking tramadol in combination with certain antidepressants or tramadol alone. Consult your doctor immediately if you experience any of the symptoms associated with this severe syndrome (see section 4 "Possible adverse effects").

Tramadol is metabolized in the liver by an enzyme. Some people have a variation of this enzyme and this can affect each person differently. In some people, it may not be possible to achieve sufficient pain relief, while others may be more likely to experience severe adverse effects. If you notice any of the following adverse effects, stop taking this medication and consult your doctor immediately: slow or shallow breathing, confusion, drowsiness, constricted pupils, general discomfort or vomiting, constipation, loss of appetite.

If you experience or have experienced any of these problems while taking this medication, please inform your doctor. He will decide whether you should continue taking this medication.

Children and adolescents

Use in children with respiratory problems:

Tramadol should not be used in children with respiratory problems, as the symptoms of tramadol toxicity can worsen in these children.

Inform your doctor if you experience any of the following symptoms while taking this medication:

Extreme fatigue, loss of appetite, severe abdominal pain, nausea, vomiting or low blood pressure. They may be indicative of adrenal insufficiency (low cortisol levels). If you have these symptoms, contact your doctor, who will decide if you need to take hormone supplements.

Taking Zaldiar with other medications

Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medication.

Important: This medication contains paracetamol and hydrochloride tramadol. Inform your doctor if you are taking any other medication that contains paracetamol or hydrochloride tramadol, so as not to exceed the maximum daily dose.

This medication should not be taken with monoamine oxidase inhibitors (MAOIs) (see "Do not take Zaldiar").

This medication is not recommended for use if you are being treated with:

• Carbamazepine (a medication normally used to treat epilepsy or some types of pain, such as severe facial pain called trigeminal neuralgia).
• Buprenorphine, nalbuphine or pentazocine (opioid analgesic). Pain relief may be reduced.

Inform your doctor or pharmacist if you are taking:

flucloxacillin (antibiotic), due to a serious risk of blood and fluid imbalance (metabolic acidosis with high anion gap) that must be treated urgently and that may occur particularly in cases of severe kidney or liver disease, sepsis (when bacteria and their toxins circulate in the blood causing organ damage), malnutrition, chronic alcoholism and if you are taking the maximum daily dose of paracetamol, especially if you are taking the maximum daily dose of paracetamol for a longer period. Metabolic acidosis with high anion gap is a serious disease that must have urgent treatment.

The risk of adverse effects increases if you are taking:

• triptans (for the treatment of migraine) or selective serotonin reuptake inhibitors, "SSRIs" (for the treatment of depression). If you experience confusion, agitation, fever, sweating, uncoordinated movements of the limbs or eyes, uncontrolled muscle contractions or diarrhea, you should call your doctor.
• other analgesics such as morphine and codeine (also when used for cough treatment), baclofen (muscle relaxant), some medications to lower blood pressure, medications for allergy treatment. You may feel drowsy or dizzy. If this occurs, consult your doctor.

The concomitant use of this medication and sedatives such as benzodiazepines or related medications increases the risk of drowsiness, respiratory difficulties (respiratory depression), coma and may be potentially fatal. For this reason, concomitant use should only be considered when other treatment options are not possible. However, if your doctor prescribes this medication with sedatives, you should limit the dose and duration of concomitant treatment.

Inform your doctor of all sedatives you are taking and follow your doctor's dose recommendation strictly. It may be helpful to inform your friends and family about the signs and symptoms mentioned above. Inform your doctor if you experience any of these symptoms.

• medications that facilitate or may cause seizures, such as certain antidepressants or antipsychotics. The risk of seizures increases if you take this medication simultaneously with these medications. Your doctor will tell you if this medication is suitable for you.
• medications for depression treatment. This medication may interact with these medications and you may experience a serotonin syndrome (see section 4 "Possible adverse effects").
• warfarin or phenprocoumon (medication used to prevent blood clots). The effectiveness of these medications may be altered, with a risk of bleeding. You should inform your doctor immediately of any prolonged or unexpected bleeding.
• gabapentin or pregabalin for treating epilepsy or pain due to nerve problems (neuropathic pain).

The effectiveness of this medication may be altered if you are also taking:

• metoclopramide, domperidone or ondansetron (medications for nausea and vomiting treatment),
• colestiramine (medication that reduces cholesterol in the blood).

Your doctor will know which medications are safe to use with this medication.

Taking Zaldiar with food and alcohol

This medication may make you feel drowsy. Alcohol may make you feel drowsy, so it is recommended not to drink alcohol while taking this medication.

Pregnancy, breastfeeding and fertility

If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.

Because this medication contains hydrochloride tramadol, it is not recommended to take this medication during pregnancy or breastfeeding. If you become pregnant during treatment with this medication, consult your doctor before taking the next tablet.

Breastfeeding

Tramadol is excreted in breast milk. For this reason, you should not take this medication more than once during breastfeeding or, if you take this medication more than once, you should stop breastfeeding.

Based on human experience, it is not suggested that tramadol affects male and female fertility. There are no data available on the combination of tramadol and paracetamol in fertility.

Driving and using machines

Ask your doctor if you can drive or use machines during treatment with this medication. It is essential to observe how this medication affects you before driving or using machines. Do not drive or use machines if you feel drowsy, dizzy, have blurred vision or double vision, or have difficulty concentrating. Be especially careful at the start of treatment, after increasing the dose, after changing the formulation, and/or when taking it with other medications.

Zaldiar contains yellow-orange colorant (E110), sodium and sulfite

This medication may cause allergic reactions because it contains yellow-orange colorant (E110). It may cause asthma, especially in patients allergic to acetylsalicylic acid.

This medication contains 179.3 mg of sodium (main component of table salt/for cooking) in each effervescent tablet. This is equivalent to 9.0% of the maximum daily sodium intake recommended for an adult. Consult your doctor or pharmacist if you need 2 or more effervescent tablets daily for a prolonged period, especially if you have been recommended a low-sodium diet.

The orange flavoring of this medication contains small amounts of sulfite that rarely may cause severe hypersensitivity reactions and bronchospasm.

Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.

Your doctor will also explain to you what you can expect from the use of Zaldiar, when and for how long you should use it, when you should contact your doctor and when you should discontinue use (see also section 2).

You should take this medication for the shortest time possible.

This medication is not recommended for children under 12 years old.

The dose should be adjusted to the intensity of the pain and your individual sensitivity. Normally, the lowest dose possible that produces pain relief should be used.

Unless your doctor prescribes otherwise, the recommended starting dose for adults and adolescents over 12 years old is 2 effervescent tablets.

If necessary, you can increase the dose as recommended by your doctor. The shortest interval between doses should be at least 6 hours.

Do not take more than 8 effervescent tablets per day.

Do not take this medication more frequently than your doctor has indicated.

Older patients

In elderly patients (over 75 years old), the elimination of tramadol may be slow. If this is your case, your doctor may recommend prolonging the dosing intervals.

Patients with liver or kidney disease/patients on dialysis

If you have any severe liver or kidney disease, treatment with this medication is not recommended. If you have moderate liver or kidney disease, your doctor may prolong the dosing intervals.

Administration form

Effervescent tablets are administered orally.

Effervescent tablets are taken dissolved in a glass of water.

If you estimate that the effect of this medication is too strong (e.g. you feel very drowsy or have difficulty breathing) or too weak (e.g. you do not have adequate pain relief), inform your doctor.

If you take more Zaldiar than you should

If you have taken more of this medication than you should, even if you feel well, consult your doctor or pharmacist immediately, as there is a risk of severe liver damage that may only become apparent later.

In case of overdose or accidental ingestion, consult the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take Zaldiar

If you forget to take a dose of this medication, it is likely that the pain will recur. Do not take a double dose to compensate for the missed doses, simply continue taking the effervescent tablets as usual.

If you interrupt treatment with Zaldiar

You should not stop taking this medication suddenly unless your doctor tells you to. If you want to stop taking your medication, talk to your doctor first, especially if you have been taking it for a long time. Your doctor will inform you when and how to discontinue it, which can be done by gradually reducing the dose to reduce the risk of unnecessary adverse effects (withdrawal symptoms).

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

Like all medicines, this medicine can cause side effects, although not everyone will experience them.

Very common: may affect more than 1 in 10 people;

• nausea,
• dizziness, drowsiness.

Common: may affect 1 in 10 people;

• vomiting, digestive problems (constipation, flatulence, diarrhea), stomach pain, dry mouth,
• itching, increased sweating (hyperhidrosis),
• headache, agitation,
• confusion, sleep disorders, mood changes (anxiety, nervousness, euphoria - feeling "high" all the time).

Uncommon: may affect 1 in 100 people;

• increased heart rate or increased blood pressure, cardiac rhythm and frequency disorders,

• tingling, numbness, or pinching sensation in the extremities, ear noises, involuntary muscle spasms,
• depression, nightmares, hallucinations (hearing, seeing, or perceiving something that does not exist in reality), memory loss,
• difficulty breathing,
• difficulty swallowing, blood in the stool,
• skin reactions (e.g. rashes, urticarial hives),
• increased liver enzyme values,
• presence of albumin in the urine, difficulty or pain urinating,
• chills, hot flashes, chest pain.

Rare: may affect 1 in 1,000 people;

• seizures, difficulty performing coordinated movements, transient loss of consciousness (syncope),
• dependence on the medication,
• delirium,
• blurred vision, pupil constriction (miosis),
• speech disorders,
• excessive pupil dilation (mydriasis).

Frequency not known:

• decreased blood sugar levels (hypoglycemia),
• serotonin syndrome, which may manifest as changes in mental state (e.g. agitation, hallucinations, coma), and other effects, such as fever, increased heart rate, unstable blood pressure, involuntary muscle contractions, muscle rigidity, lack of coordination, and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea) (see section 2 "What you need to know before starting to take Zaldiar").

The following adverse effects recognized have been reported by people who have taken medications containing only hydrochloride tramadol or only paracetamol. However, if you experience any of these symptoms while taking this medication, please tell your doctor:

• Dizziness when getting up after lying down or sitting, low heart rate, fainting, changes in appetite, muscle weakness, slower or weaker breathing, changes in mood, changes in activity, changes in perception, worsening of asthma.
• The use of this medication with anticoagulants (e.g. phenprocoumon, warfarin) may increase the risk of bleeding. Please inform your doctor immediately about any prolonged or unexpected bleeding.
• The use of paracetamol alone or when taken with the antibiotic flucloxacillin may induce an anomaly in the blood and fluids (metabolic acidosis with high anion gap) when there is an increase in plasma acidity.

• In rare cases, skin eruptions, indicating allergic reactions that may manifest as sudden swelling of the face and neck, shortness of breath, or drop in blood pressure and dizziness. If this happens, interrupt treatment and consult your doctor immediately. Do not take this medication again.

In rare cases, using a medication like hydrochloride tramadol may create dependence, making it difficult to stop taking it.

In rare instances, people who have been taking hydrochloride tramadol for some time may feel unwell if they stop treatment abruptly. They may feel agitated, anxious, nervous, or shaky. They may be hyperactive, have difficulty sleeping, and experience gastrointestinal and intestinal disorders. Very few people may also experience panic attacks, hallucinations, unusual perceptions such as itching, tingling, and numbness, and ear noises (tinnitus). If you experience any of these symptoms after stopping treatment with this medication, please consult your doctor.

Frequency not known: hiccups.

In exceptional cases, blood tests may reveal certain abnormalities, such as low platelet count, which may result in nasal or gum bleeding.

In very rare cases, severe skin reactions with paracetamol have been reported.

Tramadol has been associated with rare cases of respiratory depression.

Reporting of adverse effects:

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.

Keep this medication out of the sight and reach of children.

Store this medication in a safe and protected location, inaccessible to other individuals. This medication may cause severe harm or even be fatal to individuals who have not been prescribed it.

Do not use this medication after the expiration date appearing on the box and the aluminum strip after CAD. The expiration date is the last day of the month indicated.

Do not store at a temperature above 25°C.

Medications should not be disposed of through drains or trash. Dispose of packaging and unused medication at the SIGRE collection point at the pharmacy. If unsure, ask your pharmacist how to dispose of unused packaging and medication. By doing so, you will help protect the environment.

Composition of Zaldiar

• The active principles are hydrochloride of tramadol and paracetamol.

Each effervescent tablet contains 37.5 mg of hydrochloride of tramadol and 325 mg of paracetamol.

• The other components (excipients) are:

Sodium citrate anhydrous, anhydrous citric acid, Povidone K30, sodium hydrogen carbonate, Macrogol 6000, anhydrous colloidal silica, magnesium stearate, orange flavor (contains corn-derived maltodextrin, modified starch (E1450), natural and artificial flavors, sulfite), potassium acesulfame, sodium saccharin, yellow-orange colorant (E110).

Appearance of Zaldiar and contents of the package

White to slightly pinkish tablets with speckles of color. The tablets are packaged in aluminum-coated strips.

It is presented in boxes of 2, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 effervescent tablets.

Only some package sizes may be commercially available.

Marketing Authorization Holder

Grünenthal Pharma, S.A.

Doctor Zamenhof, 36 – 28027 Madrid, Spain

Responsible for manufacturing

Grünenthal GmbH

Zieglerstrasse 6–D- 52078 Aachen, Germany

This medicine is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:

SloveniaZaldiar®37,5 mg/325 mg effervescent tablets

SpainZaldiar®37,5 mg/325 mg effervescent tablets

FranceIxprim®37,5mg/325mg, effervescent tablet
Zaldiar®37,5mg/325mg, effervescent tablet

HungaryZaldiar®37.5 mg/325 mg, effervescent tablet

IrelandIxprim®effervescent 37.5 mg/325 mg, effervescent tablet

PortugalZaldiar®EFE 37,5mg/325 mg effervescent tablets

United Kingdom (Northern Ireland)Tramacet®37.5 mg/325 mg effervescent tablet

Last review date of this leaflet: December 2024

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/